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Background: PRDM family proteins are emerging 
as an attractive class of epigenetic drug discovery 
targets. 
Results: The histone methyltransferase PRDM9 
shows broader activities than previously recognized. 
Conclusion: PRDM9 is an archetypal member of 
the PRDM family with demonstrated chemical 
tractability. 
Significance: This work will facilitate the 
generation of small drug-like molecules/chemical 
biology probes for the PRDM family.  
 
ABSTRACT 
PRDM proteins have emerged as 
important regulators of disease and 
developmental processes. To gain insight into 
the mechanistic actions of the PRDM family, we 
have performed a comprehensive 
characterization of a prototype member protein, 
the histone methyltransferase PRDM9, utilizing 
biochemical, biophysical and chemical biology 
techniques. We report the first known molecular 
characterization of PRDM9-methylated 
recombinant histone octamer and the 
identification of new histone substrates for the 
enzyme. A single Cys321Pro mutant of the 
PR/SET domain was demonstrated to 
significantly weaken PRDM9 activity. 
Additionally, we have optimized a robust 
biochemical assay amenable to high throughput 
screening to facilitate the generation of small 
molecule chemical probes for this protein family. 
This work has provided valuable insight into the 
enzymology of an intrinsically active PRDM 
protein. 
 
In recent years, the PRDM family of proteins 
has emerged as a class of putative transcriptional 
regulators fundamental to the control of cellular 
differentiation and disease progression. Members 
of the PRDM family are characterized by a 
conserved N-terminal PR (PRDI-BF1 and RIZ1 
homologous) domain followed by a variable 
number of zinc-finger repeats. While the PR 
domain is related to the catalytic SET (Suppressor 
of variegation 3-9, Enhancer of  zeste and Trithorax) 
domain of a large group of histone lysine 
methyltransferases, the action of PRDM proteins 
can either be mediated through recruitment of 
histone-modifying enzymes (e.g. PRDM1 and -6), 
or through direct histone lysine methylation (e.g. 
PRDM2, -8 and -9) (1-8). Deregulation of PRDM 
expression has been associated with several forms 
of malignant neoplasia, including leukemia, breast 
cancer, and gastric cancer (7,9,10). In addition, a 
growing body of research has demonstrated that 




many PRDM proteins are critical for directing a 
broad range of developmental processes, from 
primordial germ cell specification to brown fat 
differentiation (8).  
To gain insight into the mechanistic action of 
this family of proteins, we have selected PRDM9 as 
a prototype enzyme for comprehensive 
characterization utilizing biochemical and 
biophysical approaches. One of seventeen members 
of the family, the histone methyltransferase 
PRDM9 was initially identified as Meisetz 
(meiosis-induced factor containing a PR/SET 
domain and zinc-finger motif), after the discovery 
of its role in controlling epigenetic events required 
for correct meiotic progression (5). Disruption of 
the PRDM9 gene in mice results in reduced double-
strand break repair, impaired gonad formation, and 
sterility (5). Subsequent studies have shown that 
PRDM9 is responsible for zinc-finger binding of 
specific DNA sequences before crossover, thus 
providing a molecular basis for recombination 
hotspot localization (11,12). More recently, meta-
analysis of clinical data sets from a range of tumors 
identified PRDM9 as a cancer-specific biomarker 
gene (13). Intrinsic methyltransferase activity of 
recombinant PRDM9 on histone H3 has been 
demonstrated and described in the literature (5,6). 
In addition, a crystal structure of mouse PRDM9 in 
complex with a histone peptide and S-
adenosylhomocysteine (SAH) is available (6). The 
availability of these resources presents a unique 
opportunity to deepen our understanding of the 
structural features governing PRDM9 activity.  
The data we have generated shows that 
PRDM9 has the potential to exhibit broad histone 
substrate recognition extending to all four 
individual histone core proteins, as well as histone 
octamers ‒ the basic building blocks of chromatin. 
Using a robust biochemical assay, we have 
accomplished the first documented characterization 
of methyltransferase activity on recombinant 
histone octamer substrates prepared by co-
expressing all four core histones (H2A, H2B, H3 
and H4) from a single polycistronic vector (14). A 
regulatory mechanism of PRDM9 enzymatic 
activity involving structural rearrangement of 
substrate and S-adenosylmethionine (SAM) 
binding sites has previously been described (6). 
Using a combination of biophysical techniques, we 
tested this hypothesis and demonstrated evidence in 
support of it. Significantly, growing knowledge 
about the biological importance and disease 
relevance of the PRDM family of proteins has 
brought to the fore their potential as novel targets in 
epigenetic drug discovery (8,15,16).  We have 
optimized a robust bioluminescent 
methyltransferase assay amenable to high 
throughput screening, to facilitate the identification 
of small molecules that modulate PRDM proteins. 
This work will help progress the development of 




Expression and purification of recombinant 
PRDM9—Recombinant plasmid of the PR/SET 
domain of PRDM9 without zinc fingers or knuckle 
was constructed (Fig. 1). Briefly, the gene encoding 
residues 192-377 of PRDM9 was cloned from full 
length mouse PRDM9 (GenBank Accession 
Number Q96EQ9), fused with a TEV-protease 
cleavage site preceeded by an N-terminal hexa-
histidine tag, and inserted into bacterial expression 
vector pNIC28-Bsa4 (GenBank Accession Number 
EF198106). The plasmid was transformed into an E. 
coli BL21-DE3 Rosetta strain (developed by the 
Protein Production Platform of Nanyang 
Technological University, Singapore) and 
expressed using a large-scale expression system 
(Harbinger Biotech, LEX). Overnight culture was 
transferred into antibiotic-containing Terrific Broth 
supplemented with 17 mM KH2PO4 and 72 mM 
K2HPO4. Induction of expression was performed at 
16°C by adding isopropyl 1-thio-β-D-
galactopyranoside to a final concentration of 0.5 
mM when Abs600 reached 2.0. Expression was 
allowed to proceed overnight and cells were 
harvested by centrifugation at 9,000 X g for 20 
minutes at 4°C, followed by sonication of cell 
pellets in 20 mM HEPES (pH 7.5), 500 mM NaCl, 
0.5 mM TCEP, 1.25 mg/ml lysozyme and protease 
inhibitors (Roche, cOmplete mini EDTA-free). Cell 
lysate was clarified by centrifugation at 30,000 X g 
for 30 minutes at 4°C, and the supernatant was 
loaded onto a 5-ml IMAC column for affinity 
purification (BioRad, Profinia), followed by size-
exclusion chromatography using a HiLoad 16/60 
Superdex 200 column (GE Healthcare, AKTA 
Express). Site-directed mutagenesis of cysteine to 
proline at residue 321 was performed using a 
synthetic primer, 5’-
GAGGTATGTGAACCCTGCCCGGGATGATG-




3' (GenScript). The bases that were changed to 
create the desired mutation are underlined. Mutant 
PRDM9 was recombinantly expressed and purified 
in similar fashion as the wild type. 
Histone substrates—Recombinant Xenopus  
laevis histone octamers (supplemental Fig. S1C and 
D) were expressed from a     single poly-cistronic 
vector and purified under non-denaturing 
conditions as previously described (14). 
Recombinant human full-length histones H2A, 
H2B, H3 and H4 were purchased from New 
England Biolabs (M2502S, M2505S, M2503S and 
M2504S). H3 peptide 1-21 (amino acid sequence 
ARTKQTARKSTGGKAPRKQLA), H3 peptide 
21-44 (amino acid sequence 
ATKAARKSAPATGGVKKPHRYRPG), and H4 
peptide 1-36 (amino acid sequence 
SGRGKGGKGLGKGGAKRHRKVLRDNIQGIT
KPAIRR) were synthesized by GenScript. 
Bioluminescent methyltransferase assay—
Enzyme activity was measured using a low-
volume, bioluminescent assay (Promega 
CS175601, Methyltransferase-Glo™) in which a 
light signal is produced from any methyltransferase 
reaction that uses SAM as cosubstrate. Reaction 
buffer consisted of 50 mM Tris (pH 8.0) with 20 
mM KCl, 5 mM MgCl2, 2 mM DTT and 10% 
glycerol. For biochemical characterization studies, 
at least 10 µl of reaction was incubated at 30oC for 
60 minutes in PCR tubes, followed by transfer of 4 
µl of reaction to duplicate wells in a 384-well plate 
(Greiner 784075). Low-volume reactions for the 
high-throughput screen format were incubated at 
30oC for 90 minutes directly in the 384-well plate 
at 4 µl per well. Reaction signals were detected 
using microplate readers on luminescent mode 
(Tecan, Safire and M1000). For Km measurements, 
reactions were performed at different 
concentrations of the substrate of interest, and 
parameters were determined by non-linear 
regression (GraphPad Prism version 5.03). 
SAH/SAM conversion curves were created to 
determine kcat values for each reaction. Enzyme 
concentrations were set within a range which gave 
linear product formation. For wild type PRDM9 
reactions with histone octamer, H3 protein, H3 
peptide 1-21 and H4 peptide 1-36, enzyme 
concentrations used were 50 nM, 100 nM, 10 nM 
and 300 nM respectively. 5 µM of mutant PRDM9 
was used in reaction with H3 peptide 1-21 to 
achieve significant background over noise. Drug 
response studies were performed at 180 nM 
PRDM9, 2.5 µM H3 peptide 1-21 and 4 µM SAM. 
All compound stock solutions were prepared in 
90% DMSO, of which 5 to 200 nl were transferred 
to the assay plate using an automated liquid handler 
(Labcyte, Echo). Enzyme and compounds were pre-
incubated in the plate for 30 minutes before 
addition of substrate. Suramin and sinefungin were 
purchased from Sigma (S2671 and S8559). Assay 
robustness was evaluated using a compound library 
(Microsource, Pharmakon) consisting of five 384-
well assay plates, with each plate containing 320 
compounds (screened at 12.5 µM), 32 wells of 
DMSO controls (vehicle controls, up to 5% DMSO) 
and 32 wells of inhibition controls (1 mM suramin). 
The intra plate controls were used to measure assay 
performance and compound biological activity (% 
inhibition) according to Equations 1 to 3. 
 Signal to noise =  DMSO control 
Inhibition control           (1) 
 Z′ =  1 − 3 X  SDDMSO control + 3 X SDInhibition control 
Abs(MeanDMSO control − MeanInhibition control)   (2) 
 % inhibition = 100(1 −
Compound RLU− MeanInhibition control 
MeanDMSO control − MeanInhibition control )        (3) 
 
Molecular modeling—The PRDM9 X-ray 
structure (PDB # 4C1Q) (6) was downloaded from 
the RCSB Protein Databank (www.pdb.org). The 
structure was prepared using the Protein 
Preparation Wizard of Maestro version 9.4 
(www.schrodinger.com). This included adding 
hydrogen atoms, assigning bond orders, setting 
protonation states, removing solvent atoms further 
than 5 Å from SAH, and optimizing the hydrogen 
bond network. SAH was replaced with a structure 
of SAM whereby all the atoms shared with SAH 
retained their coordinates, and it was verified that 
the extra methyl group of SAM did not clash with 
the protein. Cysteine at residue 321 was then 
mutated to a proline. Finally, both the wild type and 
the Cys321Pro mutant were subjected to 500 steps 
of constrained minimization with Macromodel 
version 10.0 using Polak-Ribiere-Conjugate-
Gradient (PRCG) (17), the OPLS2005 force field 
(18) and GB/SA continuum solvation model (19) 
with water as solvent. All residues further than 7Å 
from SAH were constrained using flat-bottomed 




Cartesian constraints with a force constant of 100 
kJ/mol/Å and a half width of 0 Å. 
Isothermal titration calorimetry (ITC)—ITC 
experiments were conducted using a MicroCal 
Auto-iTC200 instrument (GE Healthcare) at 25°C in 
20 mM HEPES (pH 7.5) with 50 mM NaCl. 
Depending on the binding affinities of the ligands, 
0.05 mM of enzyme was loaded in the cell with 
either 1.0 mM or 2.5 mM of ligand in the titrating 
syringe. In the case of the enzyme-substrate 
complex, 500 µM of H3 peptide 1-21 was loaded in 
the cell alongside the enzyme. A total of 20 
injections were performed with a spacing of 120 
seconds between each injection. To correct for heat 
of dilution, mixing enthalpies from titrant solution 
injections into protein-free ITC buffer were 
subtracted from all data. Data was analyzed using 
Origin 7.0 software (Origin Lab Corp.), and affinity 
was calculated using a one-site binding model.       
Differential scanning fluorimetry (DSF)—
Thermal stability of PRDM9 was measured using 
assay conditions of 10 µM recombinant protein, 0 
mM to 3 mM SAM, SAH or sinefungin (Sigma 
A7007, A9384 and S8559) and SYPRO Orange 
(Sigma S5692). Assay buffer consisted of 20 mM 
HEPES (pH 7.5) and 50 mM NaCl. Samples were 
subjected to an increase in temperature from 25°C 
to 95°C over a period of 30 minutes. For thermal 
stability analysis of enzyme-substrate complex, 150 
µM of H3 peptide 1-21 was incubated with enzyme 
prior to addition of SAM. The experiment was 
performed on a Roche 480 real-time PCR machine 
with fluorescence readings taken at each 
temperature increment. Fluorescence 
measurements were plotted using GraphPad Prism 
version 5.03, and melting curves were generated. 
Mass spectrometry (MS)—H3 peptides were 
analyzed by matrix-assisted laser desorption 
ionization time-of-flight (MALDI TOF) and 
MALDI TOF/TOF MS on a 4800 MALDI 
TOF/TOF mass spectrometer (AB Sciex) in 
positive ion mode. Samples were adjusted to pH 2.0 
with 10% trifluoroacetic acid (TFA) and desalted 
on a Oasis HLB 1cc Extraction Cartridge (Waters) 
pre-equilibrated with 0.1% TFA. Wash and elution 
steps were performed with performed 0.1% TFA 
and 50% acetonitrile (ACN)/ 0.1% TFA 
respectively. Desalted peptide solution was spotted 
onto a stainless steel MALDI plate, overlaid with 5 
mg/ml α-Cyano-4-hydroxycinnamic acid matrix 
solution in 50% ACN and 0.1% TFA, and air-dried. 
MALDI TOF MS data was recorded over a mass 
range of 800 Da to 3500 Da. Methylated peptide 
ions, judged by mass increases of multiples of 14 
Da (-CH2) over the corresponding substrate peptide 
ions, were selected for further MALDI TOF/TOF 
MS analysis. For tandem MS analysis, a 1 kV 
MS/MS operating mode was used with relative 
precursor mass window set at +/- 10 Da. MS/MS 
acquisition of selected precursors was set to 1000 
shots per spectrum with 50 shots per sub-spectrum 
using fixed laser intensity with a uniformly random 
spot search pattern.  Data was analyzed with the 
4000 Series Explorer software (AB Sciex, version 
3.7). A standard deviation of 3 was used for 
removal of noise from the spectra, and b and y 
series ions were annotated according to the peptide 
sequences. H4 peptide was analyzed using 
electrospray ionization (ESI) MS on an LTQ Velos 
Pro Orbitrap machine (Thermo Scientific) by direct 
infusion ESI at 3 µl/min through a normal API 
source. Samples were desalted using a C18 
cartridge (Sep-Pak Vac 3cc (200mg), 
Waters).Wash and elution steps were performed 
with performed 0.1% formic acid (FA), and 50% 
ACN/ 0.1% FA respectively. The mass 
spectrometer was operated using electron transfer 
dissociation (ETD) with the flowing parameter 
settings: anion target 1E7 with max injection time 
200 ms, Velos Pro ion trap MSn AGC target 1E5 
with max injection time 300 ms. ETD fragment ions 
were recorded in Velos Pro ion trap over a mass 
range of 50 Da to 2000 Da. The spectra were 
viewed with Xcalibur version 2.2 (Thermo 
Scientific) and peaks were annotated manually 
based on their charge states and sequence. Product 
size determination of all other substrates was 
performed on an Agilent 6224 LC/MS TOF system. 
 
RESULTS 
 Biochemical characterization of PRDM9 
methyltransferase activity—Enzymatic activity of 
recombinant mouse PRDM9 (residues E192-F377) 
was assessed and quantified in a bioluminescent 
methyltransferase assay which monitored 
formation of SAH, the reaction by-product of 
cosubstrate SAM (supplemental Fig. S15A and B). 
Three representative H3 substrate forms were 
utilized for characterization: recombinant histone 
octamer, recombinant full-length H3 protein, and 
synthetic H3 peptide 1-21. Reaction conditions for 
each substrate were optimized to achieve high 




signal-to-noise readings suitable for determination 
of enzyme kinetics.  
First, a dose-response experiment was 
performed with increasing concentrations of 
recombinant histone octamer (Fig. 2A). The Km 
value of PRDM9 for histone octamer was 
determined to be 0.17 µM (Table 1). A similar 
dose-response experiment using full-length H3 
protein (Fig. 2C) revealed that both histone protein 
and octamer shared highly similar Km values (Table 
1). In contrast, the Km value for H3 peptide was 
more than an order of magnitude higher at 3.21 µM. 
This suggests that PRDM9 binds octamer and H3 
protein with higher affinity than the H3 peptide 
(Table 1 and Fig. 2E). Given that histones H3 and 
H4 form a tetramer within the octameric complex, 
we extended our investigation to include a 
representative H4 substrate ‒ synthetic H4 peptide 
1-36 (Fig. 2G). We found the Km value for H4 
peptide (5.47 µM) comparable with that for H3 
peptide (Table 1).  
A second set of studies was conducted by 
titrating SAM instead of substrate, to investigate the 
affinity of PRDM9 for SAM (Fig. 2B, 2D, 2F and 
2H). In general, a trend could be observed whereby 
Km values with respect to SAM were consistently 
higher than those with respect to substrate (Table 1). 
Notably, the Km for SAM showed a 10-fold increase 
when the peptide of H4 rather than H3 was used as 
substrate. An examination of kcat values revealed 
that of the substrates tested, PRDM9 exhibited 
highest catalytic activity in reaction with H3 
peptide (Table 1). This was consistent with the fact 
that H3 peptide reactions required the least amount 
of enzyme (10 nM) to achieve high signal-to-
background assay readings. Based on this analysis, 
the H3 peptide substrate was selected for further 
development of an assay to screen small molecule 
inhibitors of PRDM9. 
A PR/SET domain mutation significantly 
diminishes PRDM9 activity—To further our 
understanding of structural features governing 
PRDM9 activity, we performed molecular 
modelling based on an existing X-ray crystal 
structure of PRDM9 in complex with SAH and a 
short H3K4me2 peptide (PDB # 4C1Q) (6). SAH 
was manually replaced by SAM, and the resulting 
complex was subject to constrained energy 
minimization (Fig. 3A). Close examination of the 
PR/SET domain showed that the amino acid 
backbone of cysteine residue 321 formed two 
hydrogen bonds with the adenosyl moiety of SAM 
(Fig. 3A). In certain members of the PRDM family 
for which intrinsic methyltransferase activity has 
yet to be demonstrated (e.g. PRDM1 and PRDM10), 
this position carries a proline residue instead of 
cysteine (supplemental Fig. S2). We hypothesized 
that replacing Cys321 with Pro321 in PRDM9 
(PRDM9-C321P) would disrupt SAM interactions, 
since the backbone of proline would not be able to 
form the hydrogen bonds observed in the wild type 
X-ray structure. The structure complex of PRDM9-
C321P with SAM and H3K4me2 was subject to 
constrained energy minimization. We observed a 
rotation of the adenosyl moiety of SAM away from 
Pro321 due to steric repulsion from the proline ring 
(Fig. 3B). As a result, no hydrogen bonds between 
Pro321 and SAM were formed. However, not all 
SAM interactions were affected by the mutation ‒ 
the methionine moiety of SAM was still favorably 
positioned to form hydrogen bonds with Leu258 
and Tyr291 (Fig. 3B).  
Based on the structural model, we predicted 
that a single Cys321Pro mutation would weaken 
PRDM9 catalytic activity through disruption of 
interactions with SAM. A mutant Cys321Pro 
construct of PRDM9 was generated through site-
directed mutagenesis of the wild type construct, and 
recombinant PRDM9-C321P enzyme was 
expressed and purified (supplemental Fig. S1A and 
B). We assessed PRDM9-C321P methyltransferase 
activity using the earlier described biochemical 
assay. Our first attempts to characterize PRDM9-
C321P reactions with H3 peptide were conducted 
using assay conditions similar to those for the wild 
type. However, these resulted in no detectable 
activity (data not shown). A direct comparison of 
the wild type and mutant enzyme dose-response 
curves revealed that wild type PRDM9 exhibited a 
linear increase in activity between enzyme 
concentrations 0 nM to 80 nM, whereas no activity 
was detected for the mutant enzyme at the 
corresponding concentration range (supplemental 
Fig. S3A). Rather, enzyme concentrations over two 
orders of magnitude higher (≥ 5 µM), were required 
for significant mutant activity to become apparent 
(supplemental Fig. S3B). Biochemical 
characterization of PRDM9-C321P activity was 
subsequently carried out using 5 µM of enzyme 
(supplemental Fig. S3C and D). The weakened 
catalytic activity resulting from the Cys321Pro 
mutation was further emphasised by the striking 




decrease in kcat values of over 500-fold from wild 
type PRDM9 (Table 1).  
Biophysical characterization of PRDM9—
Binding properties of wild type and mutant PRDM9 
were characterized using ITC. PRDM9 and 
PRDM9-C321P bound H3 peptide substrate with 
dissociation constants of 17.6 µM and 31.5 µM 
respectively, while PRDM9 bound SAM with a 
dissociation constant of 42.6 µM (Table 2 and Fig. 
4A – C). Conversely, no binding between PRDM9-
C321P and SAM was detectable. Through DSF 
analysis, we demonstrated that PRDM9-C321P had 
a decreased thermal stability of 2°C compared to 
wild type PRDM9, suggesting an adverse effect on 
structural integrity caused by the mutation 
(supplemental Fig. S4). In addition, we observed 
significantly weaker thermal shifts for PRDM9-
C321P (Fig. 5B, black) as compared to the wild 
type (Fig. 5A, black) in response to SAM. On the 
other hand, differences between PRDM9 and 
PRDM9-C321P thermal shifts in response to H3 
peptide were comparatively less pronounced (Fig. 
5C). The biophysical data described above 
reiterates the importance of residue Cys321 in 
facilitating PRDM9 interactions with SAM. Two 
SAM analogues, SAH and sinefungin 
(supplemental Fig. S15B and C), were also 
investigated for binding to PRDM9 and PRDM9-
C321P. No significant thermal shift was observed 
for SAH with both enzymes (Fig. 5A and B, blue). 
Sinefungin binding resulted in modest thermal 
shifts for the wildtype, and none for the mutant (Fig. 
5A and B, red).  
Until recently, all available X-ray crystal 
structures for PRDM family proteins lacked bound 
cosubstrate or substrates (e.g. PRDM2 (20), 
PRDM11 and PRDM12; PDB # 2QPW, 3RAY and 
3EP0 respectively). Wu et al. (6) described the first 
reported PRDM-family ternary structure complex 
(PDB # 4C1Q) involving PRDM9, SAH and H3 
peptide as earlier mentioned. It was further 
proposed that in the absence of substrate and 
cosubstrate molecules, PRDM9 would undergo 
structural rearrangement resulting in an auto-
inhibited state (6). Notably, in an earlier unbound 
crystal of PRDM9 (PDB # 4IJD), the post-set 
domain structure was incomplete. We hypothesized 
that events involving PRDM9 substrate and 
cosubstrate binding were closely related, and that 
binding at one site of the enzyme would create 
favorable conditions for binding at the other.  
We tested this hypothesis using ITC as a tool 
to measure thermodynamic Gibbs free energy 
changes (ΔG) in response to PRDM9 substrate and 
cosubstrate binding. Data from two experiments 
were compared: 1) SAH binding with uncomplexed 
PRDM9, and 2) SAH binding with PRDM9 
complexed with H3 peptide 1-21. While no 
thermodynamic changes were observed for 
uncomplexed PRDM9 (data not shown), a strong 
binding curve was generated between SAH and the 
PRDM9/H3 peptide complex (Fig. 4D). Highly 
negative ΔG values indicated favorable or 
spontaneous binding between SAH and PRDM9 
when its substrate binding site was occupied (Fig. 
4D). This finding was corroborated using DSF as a 
second biophysical approach, with the actual 
cosubstrate SAM as a binding partner. Thermal 
shifts for wild type PRDM9 (Fig. 5A, black) were 
qualitatively compared with those for the 
PRDM9/H3 peptide complex in response to SAM 
(Fig. 5A, green). Complexed PRDM9 showed more 
significant thermal shifts with increasing 
concentrations of SAM as compared with PRDM9 
alone. Not surprisingly, this trend was not observed 
in the case of PRDM9-C321P (Fig. 5B, black and 
green), since the mutation had been specifically 
designed to interfere with SAM binding. The above 
results lend biophysical support to the hypothesis 
that substrate binding to PRDM9 creates favorable 
conditions for its interaction with SAM. 
Molecular characterization of histone 
substrate modification—Having demonstrated 
active methylation of histone octamers by PRDM9 
in a biochemical assay (Table 1), we proceeded to 
identify which core histone units of the octamer 
were modified. Molecular characterization of 
substrate modification was performed by mass 
spectrometry analysis to determine the methylation 
status of each histone protein. Individual histone 
peaks were clearly identifiable and well-separated 
in ESI-TOF mass spectra for the unmodified 
octamer (supplemental Fig. S1D). In our analyses 
of octamer reaction product formation, we observed 
a time and enzyme dependent increase in 
methylation of all four core histone units H2A, H2B, 
H3 and H4 (supplemental Fig. S5 – 7). Of these, 
PRDM9 showed the greatest propensity for 
methylating H3 within the octamer (Table 3).  
Similar molecular characterization was 
performed on the individual histone recombinant 
proteins H2A, H2B, H3 and H4.  Again, we 




observed methylation of all core histones by 
PRDM9 (supplemental Fig. S8), with the H3 
substrate being the most highly modified (Table 3). 
No modification of substrate was detected in any 
reactions involving PRDM9-C321P (data not 
shown), leading us to conclude that the Cys321Pro 
mutation had completely abolished methylation of 
whole histone proteins.  The enzymatic behaviour 
of PRDM9 appears to be the same whether        
presented with octamer or individual histone 
protein as substrate (Fig. 6A).  
It is known that methylation of N-terminal 
histone tails in the nucleosome regulate gene 
expression. The histone tail length for H3 is 38 
residues, and that for H4 is 26 residues (21). With 
this in mind, we characterized the product 
formation in PRDM9 reactions with peptides 
comprising histone tail sequences: H3 peptide 1-21 
and H3 peptide 21-44, as well as H4 peptide 1-36. 
In reactions consisting of excess enzyme and SAM, 
all histone peptide substrates were modified within 
the first hour (Fig. 6B – D). Clear conversion of 
substrate to methylated product could be observed 
from the mass spectra of each peptide (Fig. 6B – D). 
Interestingly, the combined maximum methylation 
observed for both H3 peptides came close to that for 
whole H3 protein alone (Table 3). 
Hayashi et al. previously reported that 
PRDM9 activity was restricted to H3K4me2, while 
Wu et al. more recently described mono-, di- and 
tri-methylation of H3K4, as well as possible 
methylation of H3K9 (5,6). The number of 
methylations reported for H3 in Table 3 had been 
based on saturating reaction conditions, and hence 
were representative of the highest enzymatic 
activity in vitro. We explored H3 peptide 1-21 
substrate modification under controlled conditions 
that were determined by scaling respective Km 
values for substrate and cosubstrate based on the 
PRDM9 concentration used in the bioluminescent 
methyltransferase assay. In contrast to the previous 
saturating reaction (Fig. 6B), not all H3 peptide was 
fully modified in this case (Fig. 7B). The formation 
of +1 Me, +2 Me and +3 Me product was observed 
similar to that previously reported (6). In this study, 
we have attempted to unequivocally identify this 
methylation site in H3, using H3 peptide 1-21 
containing four lysine residues at K4, K9, K14 and 
K18. Using MALDI TOF/TOF MS, we 
demonstrated categorically that H3K4 was mono-, 
di-, and tri-methylated by PRDM9 (supplemental 
Fig. S11). Time point analysis showed that this 
particular methylation pattern was achieved within 
minutes, and that extending reaction time up to 3 
hours did not result in formation of new product 
(supplemental Fig. S9). With the mutant enzyme 
PRDM9-C321P, only the mono-methylated H3K4 
product was detectable (Fig. 7C and supplemental 
Fig. S10). MALDI TOF/TOF MS analysis of the 
earlier described H3 peptide 1-21 reaction under 
saturating conditions of enzyme and SAM (Fig. 6B) 
revealed additional methylation sites at K9 and K18 
(supplemental Fig. S12).  
Having demonstrated the use of MS/MS in 
the identification of specific histone methylation 
sites on a H3 peptide, we analysed a peptide 
representative of the histone tail of H4. The H4 
peptide 1-36 had earlier been characterized for 
substrate modification under saturating PRDM9 
reaction conditions (Fig. 7D).  As was the case for 
the H3 peptide, scaling down the H4 peptide 
reaction to more controlled conditions resulted in 
less product formation. At low levels of SAM, only 
the mono-methylated product of H4 peptide was 
apparent (supplemental Fig. S13). Using ESI ETD 
MS/MS analysis, we identified the methylation site 
to be H4K20me (supplemental Fig. S14), a mark 
often linked to transcriptional repression (15). The 
di-methylated product was detectable at higher 
levels of SAM (supplemental Fig. S13).    
Inhibition assay and compound library 
screen—A low-volume inhibition assay for 
PRDM9 was optimized based on the earlier 
described biochemical assay and dose-response 
studies were performed. We found that suramin 
(supplemental Fig. S15D), a known histone 
methyltransferase inhibitor (22), inhibited PRDM9 
with a reproducible IC50 of 50.5 ± 26.5 µM (Fig. 
8A). Sinefungin, a fungal compound and analog of 
SAM, gave a less potent IC50 of 357.3 ± 61.9 µM 
(Fig. 8B). In order to evaluate assay performance 
and robustness, we applied a high-throughput 
screen format to the assay using a small library of 
1,600 bioactive compounds. Several hits were 
observed whereby 12.5 µM of compound gave rise 
to more than 40% inhibition (Fig. 8C). Assay 
signal-to-noise was consistently above 9.5 
(supplemental Table S1), a satisfactory window for 
distinguishing between active and inactive 
compounds. Another measure of assay robustness, 
the Z’ factor, was determined to account for 
variability in the maximum and baseline signals. 




The average Z’ factor (> 0.72) among all the plates 
screened met the acceptance criteria for assay 
validation (23). The indicators described 
demonstrate the robustness and reproducibility of 
this assay for evaluating PRDM9-modulating 
compounds. Significantly, we have taken the first 
step towards screening a larger chemical space to 




Several recent studies have highlighted the role 
of PRDM9 in meiotic progression, providing 
important insight into molecular mechanisms 
underlying recombination initiation (11,24-26). In 
PRDM9-deficient mouse testis, impaired meiotic 
gene transcription was observed with a concurrent 
decrease in H3K4 trimethylation (5). The 
enrichment of H3K4me3 at yeast and mouse 
initation sites provided further evidence for 
epigenetic control of recombination hotspot 
specification (27-29). Consequently, the H3K4 
methyltransferase activity of PRDM9 has been an 
area of significant interest (6,30,31).  
Our findings show that the propensity of 
PRDM9 to catalyze histone lysine methylation is 
far more extensive than previously recognized. We 
have characterized the activity of recombinantly 
expressed PRDM9 using a broad range of histone 
substrates ‒ including histone octamers, whole 
histones and histone peptides ‒ and demonstrated, 
for the first time, that PRDM9 methylates all four 
core histone units H2A, H2B, H3 and H4. A 
comparison of substrate modification under 
standardized reaction conditions revealed that 
methylation of H3 was most prevalent among the 
four core histones. We performed further molecular 
characterization of H3 and H4 peptides which were 
representative of amino-terminal histone tails 
commonly subject to post-translational 
modifications. MS/MS analysis of site-specific 
histone modification presented indisputable 
evidence that H3K4 was mono-, di- and tri-
methylated by PRDM9. Interestingly, two 
additional lysines on the H3 peptide, H3K9 and 
H3K18, were observed to have undergone di- and 
mono-methylation respectively in the same 
enzymatic reaction. In the case of the H4 peptide, 
another novel methylation site was detected at 
H4K20, which had undergone mono- and di-
methylation.  
The identification of novel histone substrates of 
PRDM9 opens up new possibilities for its 
involvement in additional epigenetic processes. 
While not much is known about the role of H3K18 
methylation, di-methylated H3K9 and H4K20 are 
well-characterized histone marks associated with 
transcriptionally silent or repressed genes, while 
H3K4me3 is a hallmark of transcriptionally active 
genes (15). Some members of the PRDM family 
show strong context dependency and bidirectional 
transcriptional activity, e.g. PRDM2 action in 
response to oestrogen levels, and PRDM16 
function during brown fat specification (7,32,33). 
The concomitant occurrence of activating and 
repressive marks mediated by PRDM9 raises the 
question of whether it can exhibit diverse functions 
under different cellular conditions. Another point to 
consider is the physiological relevance of these 
novel methylation sites. While PRDM9-mediated 
H3 methylation is reasonably well-understood in 
the context of meiotic hotspot localization, the 
biological functions of H2A, H2B and H4 
methylation by PRDM9 are unknown. It would be 
premature to conclude if novel histone substrates 
methylated by PRDM9 under in vitro conditions 
would display the same modifications under 
physiological or pathological settings. Until further 
investigation is performed, there also remains the 
possibility that substrate recognition of PRDM9 
could extend to non-histone proteins, as has been 
demonstrated for other histone lysine 
methyltransferases such as SMYD2 (non-histone 
substrate p53)  and NSD1 (non-histone substrate 
NFκb) (34). 
Although the PRDM family members have 
been implicated in multiple disease and 
developmental processes, relatively little is known 
about their mechanisms of action. To date, intrinsic 
methyltransferase activity has been demonstrated 
only for a few members of the family (e.g. PRDM2, 
-8 and -9) (7,8). To better understand structural 
features governing PRDM9 methyltransferase 
activity, we designed and engineered a PR/SET 
domain mutant of PRDM9, utilizing a systematic 
approach comprising sequence alignment, 
molecular modelling and rational site-directed 
mutagenesis. Our biochemical data revealed that 
the introduced mutation, Cys321Pro, was able to 
cause significant reduction in PRDM9 catalytic 
activity; this was predicted to be a result of 
disrupted SAM binding. Using biophysical 




methods, we have demonstrated that the ability of 
mutant PRDM9 to bind SAM was indeed 
compromised to a significant degree as compared 
to the wild type.  
PRDM proteins differ from other histone lysine 
methyltransferases in their PR/SET domains, which 
share only 20‒30% sequence identity with classical 
SET domains (8,35). While SET domain 
methyltransferases have frequently been co-
crystallized with SAM, no similar co-crystal 
structures have been reported for the PRDM family. 
Remarkably, all available PRDM family structures 
are in the unbound form, with the exception of a 
PRDM9/H3 peptide/SAH co-crystal structure (6). 
Interestingly, the unbound structure of PRDM9 
displayed a conformational change in the post-set 
domain which resulted in a possible autoinhibited 
state (6). Based on the above observations, we 
speculated that histone substrate binding of 
PRDM9 selected for a conformation favorable for 
SAM binding. We utilized the loss-of-binding 
PR/SET domain mutant of PRDM9 as a tool for 
further investigation. Clear increases in SAM and 
SAH binding were observed when wild type 
PRDM9 was pre-complexed with a H3 peptide 
substrate in ITC and DSF experiments, compared 
with binding to the enzyme alone. No increase in 
binding was observed when the PRDM9 mutant 
was pre-complexed with the substrate. Our data 
provides biophysical evidence that PRDM9 shows 
greater propensity for SAM binding when its 
histone substrate binding site is occupied, and 
corroborates the structural observations of Wu et al. 
(6). Further investigation of this structural 
phenomenon in other members of the PRDM 
family could steer new approaches for the 
formation of high resolution co-crystal structures.  
The close relationship between SAM and 
histone substrate binding is further reflected in our 
enzyme kinetics characterization, whereby a range 
of SAM affinities were observed for different 
histone substrate reactions with PRDM9. For 
example, while both H3 and H4 peptides displayed 
similar substrate-binding affinities for PRDM9, the 
Km value for SAM was ten-fold higher for the H4 
peptide. An earlier  report showed efficient PRDM9 
methylation of H3 peptides in a coupled fluorescent 
assay, but no methylation of H4K20 peptide (6). 
This can be explained by the higher Km value for 
SAM in the H4 reaction, which suggests that higher 
SAM concentrations would be needed for 
detectable activity.  
Epigenetic drug development has gained 
considerable interest in light of recent progress in 
small-molecule modulation of methylation-
dependent pathways. Selective inhibitors of two 
histone lysine methyltransferases, EZH2 and 
DOT1L, have shown efficacy in preclinical proof-
of-concept studies and entered Phase I clinical trials 
for diffuse large B-cell and follicular lymphoma, 
and MLL-rearranged leukemia, respectively 
(36,37). These successes bring to the fore the 
potential of other histone lysine methyltransferases, 
including the PRDM family, as novel epigenetic 
drug targets. A body of work has described the 
emerging roles of PRDM proteins in diverse cancer 
types, including leukemia, breast cancer and 
stomach cancer. Currently, the disease biology and 
mechanisms of action for the PRDM family are not 
well-understood (7,8). In order to ascertain their 
therapeutic relevance and identify opportunities for 
pharmacological modulation, further 
characterization of PRDM proteins would be 
needed.  
Through a combination of biochemical, 
biophysical and chemical biology techniques, we 
have characterized a prototype member of the 
PRDM family, PRDM9, and acquired fresh 
perspective about its enzymatic action. In addition, 
we have optimized a robust biochemical assay for 
PRDM9 and demonstrated its chemical tractability 
through a small library screen of bioactive 
compounds. The application of this assay to a high 
throughput screen format can facilitate the 
generation of small molecule chemical probes for 
this protein family. It is our hope that this work will 
pave the way to the discovery of small drug-like 
molecules/chemical biology probes which the 
community can use to explore new therapeutic 
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FIGURE 1. A. Schematic depiction of the PR/SET domain (yellow), zinc knuckle (green), and zinc fingers 
(blue) of full-length mouse PRDM9. B. Recombinant mouse PRDM9 construct consisting of the PR/SET 
domain (yellow) and a hexahistidine tag/TEV protease recognition site (red). 
  
FIGURE 2. PRDM9 enzymatic activities were characterized for a series of histone substrates using an in 
vitro bioluminescent methyltransferase assay. Substrate and SAM titration curves are shown for wild type 
PRDM9 reactions using (A-B) histone octamer, (C-D) full- length H3 protein, (E-F) H3 peptide 1-21, and 
(G-H) H4 peptide 1-36 as substrates. The concentrations of PRDM9 in the reactions were 50 nM, 100 nM, 
10 nM and 300 nM respectively.  
 
FIGURE 3. Molecular models showing PR/SET domain interactions. A. PRDM9 wildtype. B. PRDM9-
C321P mutant. The PRDM9 X-ray structure (PDB # 4C1Q) was used as a template for SAM docking, 
which was followed by energy minimization.  
 
FIGURE 4. Biophysical characterization of binding using isothermal calorimetry. A. PRDM9 and H3 
peptide 1-21. B. PRDM9 and SAM. C. PRDM9-C321P and H3 peptide 1-21. D. PRDM9/H3 peptide 1-21 
and SAH.  
 
FIGURE 5. Differential scanning fluorimetry was performed to measure protein thermal shifts in response 
to binding. A. Dose response thermal shifts of PRDM with respect to SAM and SAM analogues. B. Dose 
response thermal shifts of PRDM9-C321P with respect to SAM and SAM analogues. C. Dose response 
thermal shifts of PRDM9 and PRDM9-C321P with respect to H3 peptide 1-21. 
 
FIGURE 6. A. Bar graph comparison of the maximum methylation numbers observed in H2A, H2B, H3 
and H4 derived from histone octamer and histone protein. B-D. Mass spectra of negative controls and 
PRDM9 reactions for the substrates H3 peptide 1-21, H3 peptide 21-44 and H4 peptide 1-36 respectively. 
15 µM peptide, 10 µM of PRDM9 and 1 mM SAM were used in all reactions. 
 
FIGURE 7. Mass spectra show substrate peaks representing (A) H3 peptide 1-21 control, (B) H3 peptide 
1-21 methylation by 100 nM PRDM9, and (C) H3 peptide 1-21 methylation by 5µM PRDM9-C31P.  40 
µM SAM was used in both reactions. 
 
FIGURE 8. Low-volume inhibition assay for PRDM9. A. Dose-response inhibition by suramin. B. Dose-





Kinetic parameters of wild type and mutant PRDM9 activity 
Enzymatic activities of wild type and mutant PRDM9 were characterized for a series of histone 
substrates. 
  





























TABLE 2   
Measurement of dissociation constants for wild type and mutant PRDM9 
 




Binding of H3 peptide, SAM and SAH to wild type and mutant PRDM9 was investigated using 

































TABLE 3   
Molecular characterization of PRDM9 substrate modification  
 




PRDM9 substrate modification of histone octamer, histone protein and histone peptide was characterized 











































































































Figure 4  
 



































































Characterization of the histone methyltransferase PRDM9 
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